Brief: Krystal Biotech Granted FDA Meeting For KB707 For October
21/08/2025 17:43
Aug 21 (Reuters) - Krystal Biotech Inc KRYS.O: KRYSTAL BIOTECH ANNOUNCES UPDATE ON DEVELOPMENT PLANS FOR ONCOLOGY PROGRAM KB707 AND PRIORITIZATION OF INHALED KB707 FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER KRYSTAL BIOTECH INC - GRANTED FDA MEETING FOR KB707 FOR OCTOBER KRYSTAL BIOTECH INC - INHALED KB707 SAFE, NO GRADE 4 OR 5 ADVERSE EVENTS KRYSTAL BIOTECH INC - PAUSES ENROLLMENT IN OPAL-1 STUDY KRYSTAL BIOTECH INC - ENROLLMENT CONTINUES IN KYANITE-1 STUDY FOR INHALED KB707 KRYSTAL BIOTECH INC: CO MAY ADJUST DEVELOPMENT PLANS FOR INTRATUMORAL KB707 Source text: ID:nGNXbBLWd2 Further company coverage: KRYS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Krystal Biotech
See all newsBrief: Krystal Biotech Announces Positive Clinical Data For New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression In Patients With Gorlin Syndrome
Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Krystal Biotech Q2 revenue rises on VYJUVEK strength
Brief: Krystal Biotech - Files Response With Uspto On Kb801 Patent Application - SEC Filing
Construction firm Tutor Perini jumps on S&P SmallCap inclusion